This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
by Zacks Equity Research
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
by Zacks Equity Research
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
PETQ vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
by Zacks Equity Research
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
BAX or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
IoMT Becomes the Buzzword in New Age MedTech Investing
by Urmimala Biswas
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
by Zacks Equity Research
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
Boston Scientific (BSX) Up 1.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BAX vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) raises the revenue guidance for fiscal 2019.
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
FDA Resets PAD Guidelines: The Road Ahead for Device Makers
by Urmimala Biswas
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
by Zacks Equity Research
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Boston Scientific Rides on New Products Amid Dull Pacer Sales
by Zacks Equity Research
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Top Analyst Reports: Amgen, Uber, Mondelez & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Amgen (AMGN), Uber (UBER) and Mondelez (MDLZ).
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines
by Zacks Equity Research
Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.
Boston Scientific (BSX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and -0.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?